Pharmacology of inhibitors of Janus kinases - Part 1: Pharmacokinetics

Abstract

The use of Janus kinase inhibitors for the treatment of chronic inflammatory diseases is increasingly establishing itself as a treatment option for several indications. In order to make clinical use efficient, pharmacological knowledge of the JAK/STAT signaling pathway and the special features of the pharmacokinetics of the individual drugs is essential. The JAK/STAT signaling pathway is regulated at several levels (receptor, kinase, STAT and SOCS levels), so when Janus kinase inhibitors are used, the clinically relevant pharmacodynamics are highly dependent on the dose regimen, treated indication, comedication and comorbidity. For all practical purposes, it is therefore of great importance to recognize that the factors mentioned above can have a relevant influence on the therapeutic benefit of the use of Janus kinase inhibitors. Against this background, it is particularly important to use the Janus kinase inhibitors in accordance with their approval.